PMID- 12840235
OWN - NLM
STAT- MEDLINE
DCOM- 20031201
LR  - 20181130
IS  - 1042-3931 (Print)
IS  - 1042-3931 (Linking)
VI  - 15
IP  - 7
DP  - 2003 Jul
TI  - Prospective evaluation of early abciximab and primary percutaneous intervention 
      for patients with ST elevation myocardial infarction complicated by cardiogenic 
      shock: results of the REO-SHOCK trial.
PG  - 385-9
AB  - OBJECTIVE: Patients with acute myocardial infarction complicated by cardiogenic 
      shock have a high mortality despite the use of early reperfusion therapies with 
      thrombolysis or percutaneous coronary intervention (PCI). Therefore, there is 
      still need to evaluate therapy strategies in these patients. DESIGN: The 
      REO-SHOCK trial was a prospective, non-randomized study, aimed at evaluation of a 
      routine strategy of early abciximab and PCI in a high-risk group of acute ST 
      elevation myocardial infarction (STEMI) patients with cardiogenic shock. RESULTS: 
      Patients (n = 40) planned for coronary angioplasty or stenting received abciximab 
      (0.25 mg/kg bolus followed by 0.125 mg/kg/minute over 12 hours), heparin and 
      aspirin. The intervention was successful in 92.5% of the patients and achieved 
      Thrombolysis In Myocardial Infarction (TIMI) grade 3 patency in 32 patients 
      (80%). The primary endpoint, total mortality after 30 days, was observed in 42.5% 
      (17/40), and was significantly different between patients aged > 75 years and 
      patients aged 75 years (91% versus 24%, respectively; p < 0.001). Major bleeding 
      occurred in 2 patients (5%), but stroke occurred in none. CONCLUSION: A strategy 
      of abciximab with primary PCI in high-risk patients with cardiogenic shock is 
      safe, associated with a high procedural success rate and seems to improve 
      outcomes in patients < 75 years old.
FAU - Zeymer, Uwe
AU  - Zeymer U
AD  - Medizinische Klinik II, Klinikum Kassel, Germany. Uwe.Zeymer@t-online.de
FAU - Tebbe, Ulrich
AU  - Tebbe U
FAU - Weber, Michael
AU  - Weber M
FAU - Vohringer, Hans F
AU  - Vohringer HF
FAU - Jaksch, Rainer
AU  - Jaksch R
FAU - Bischoff, Karl-Otto
AU  - Bischoff KO
FAU - Toepel, Wolfgang
AU  - Toepel W
FAU - Marsalek, Parvaneh
AU  - Marsalek P
FAU - Horn, Stefan
AU  - Horn S
FAU - Neuhaus, Karl-Ludwig
AU  - Neuhaus KL
CN  - ALKK Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Invasive Cardiol
JT  - The Journal of invasive cardiology
JID - 8917477
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - X85G7936GV (Abciximab)
SB  - IM
EIN - J Invasive Cardiol. 2003 Sep;15(9):519
MH  - Abciximab
MH  - Adult
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*methods
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunoglobulin Fab Fragments/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/complications/*drug therapy/mortality/*therapy
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Prospective Studies
MH  - Shock, Cardiogenic/*drug therapy/etiology/mortality/*therapy
MH  - Stents
EDAT- 2003/07/04 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/07/04 05:00
PHST- 2003/07/04 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/07/04 05:00 [entrez]
PST - ppublish
SO  - J Invasive Cardiol. 2003 Jul;15(7):385-9.